The Future
Read all articles from Edition 1 of the ESMO Perspectives.
All articles
Collaboration
Read all articles from Edition 6 of the ESMO Perspectives.
How to make the right therapeutic choice for cancer patients at a time of crisis
Patients with cancer and research: will COVID-19 further damage opportunities to join experimental trials?
Telemedicine: the good and bad of living a hype
“What would have been unthinkable before became feasible in the interest of patient safety”
Challenges
Read all articles from Edition 7 of the ESMO Perspectives.
Boundaries
Read all articles from Edition 8 of the ESMO Perspectives.
"Oncologists have learnt many lessons from the COVID-19 pandemic"
Dr Stefan Zimmermann, ESMO Perspectives Editor-in-Chief, explains the key aspects of a new scenario in oncology emerging from the COVID-19 pandemic.
Switching from intravenous to oral or subcutaneous cancer treatment: a sustainable approach?
Despite alternative modes of administering anticancer medicines have reinforced the idea that at-home cancer care may be sometimes feasible as well as preferred by patients, there are concerns about costs of and accessibility to these new opportunities.
Young oncologists in the coronavirus crisis: a learning opportunity
Despite some share the concern of having their career plans delayed or disrupted by the pandemic, the new challenges emerged in these unprecedented times represent a unique opportunity to grow-up as oncology professionals and get ready to a new scenario where team working, humanisation of care and virtual education will be more crucial than ever.
What role for real-world evidence in cancer research?
With the growing use of real-world evidence (RWE) to support regulatory approvals of new anti-cancer medicines in Europe and the USA, can this type of research ensure greater inclusion of women, the elderly, diverse ethnic groups, those with rare cancers and other under-represented populations in oncology studies?
The “holy grail” of lung cancer research: bring the immune system into every tumour
With multiple new therapies available, Prof. Johan Vansteenkiste says the search is on for biomarkers to better match patients to treatments
Could the daunting biology of small-cell lung cancer provide the key to elucidating drug resistance?
At ELCC 2021, Prof. Fiona Blackhall sees hope for improving patients’ poor prognoses on the horizon